From: Recent advances in the diagnosis and treatment of bladder cancer
Markers | Overall sensitivity, % | Overall specificity, % | Sensitivity for high-grade tumors, % | Point-of-care test | Interferenceb | Comments |
---|---|---|---|---|---|---|
Aneuploidy detection kitc | 30 to 72 | 63 to 95 | 66 to 70 | No | No | Expensive and laborious |
Microsatellite analysis | 58 | 73 | 90 | No | No | Expensive and laborious |
Gene microarray | 80 to 90 | 62 to 65 | 80 | No | No | Expensive and laborious |
Monoclonal antibodiesd | 76 to 85 | 63 to 75 | 67 to 92 | No | Yes | Good sensitivity in low-grade tumors, affected by BCG |
NMP 22 | 49 to 68 | 85.8 to 87.5 | 75 to 83 | Yes | Yes | Low sensitivity, affected by benign conditions |
Physician-use BTA immunoassaye | 57 to 83 | 68 to 85.7 | 61.5 | Yes | Yes | Low sensitivity, affected by benign conditions and BCG |
Quantitative laboratory BTA immunoassayf | 53 to 91 | 28 to 83 | 77 | No | Yes | Low sensitivity, affected by benign conditions and BCG |
Cytokeratins | 12 to 85 | 75 to 97 | 33 to 82 | No | Yes | Low sensitivity, affected by benign conditions and BCG |
Survivin | 53 to 90 | 88 to 100 | 50 | No | No | Low sensitivity, expensive and laborious |